The Journal of Visualized Experiments (JoVE) is a peer reviewed, PubMed-indexed video journal. Our mission is to increase the productivity of scientific research.
This article is a part of JoVE General. If you think this article would be useful for your research, please recommend JoVE to your institution's librarian.
You do not have access to any JoVE content through your current IP address.
IP: 54.234.126.92, User IP: 54.234.126.92, User IP Hex: 921337436
Current Access Through Your Registered Email Address
You aren't signed into JoVE. If your institution subscribes to JoVE, please sign in or create an account with your institutional email address to access this content.
The JoVE video player is compatible with HTML5 and Adobe Flash. Older browsers that do not support HTML5 and the H.264 video codec will still use a Flash-based video player. We recommend downloading the newest version of Flash here, but we support all versions 10 and above.
Unable to load video. Please check your Internet connection and reload this page. If the problem continues, please let us know and we'll try to help.
An unexpected error occurred. Please check your Internet connection and reload this page. If the problem continues, please let us know and we'll try to help.
Liebig, T. M., Fiedler, A., Zoghi, S., Shimabukuro-Vornhagen, A., von Bergwelt-Baildon, M. S. Generation of Human CD40-activated B cells. J. Vis. Exp. (32), e1373, doi:10.3791/1373 (2009).
Schultze, J.L. et al., CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Invest 100 (11), 2757-2765 (1997).
Schultze, J.L., Grabbe, S., & von Bergwelt-Baildon, M.S., DCs and CD40-activated B cells: current and future avenues to cellular cancer immunotherapy. Trends Immunol 25 (12), 659-664 (2004).
von Bergwelt-Baildon, M. et al., CD40-activated B cells express full lymph node homing triad and induce T-cell chemotaxis: potential as cellular adjuvants. Blood 107 (7), 2786-2789 (2006).
Wiesner, M. et al., Conditional immortalization of human B cells by CD40 ligation. PLoS ONE 3 (1), e1464 (2008).
Urashima, M., Chauhan, D., Uchiyama, H., Freeman, G.J., & Anderson, K.C., CD40 ligand triggered interleukin-6 secretion in multiple myeloma. Blood 85 (7), 1903-1912 (1995).
Lapointe, R., Bellemare-Pelletier, A., Housseau, F., Thibodeau, J., & Hwu, P., CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells. Cancer Res 63 (11), 2836-2843 (2003).
von Bergwelt-Baildon, M.S. et al., Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application. Blood 99 (9), 3319-3325 (2002).
Kondo, E. et al., CD40-activated B cells can be generated in high number and purity in cancer patients: analysis of immunogenicity and homing potential. Clin Exp Immunol 155 (2), 249-256 (2009).
Mason, N.J. et al., RNA-loaded CD40-activated B cells stimulate antigen-specific T-cell responses in dogs with spontaneous lymphoma. Gene Ther 15 (13), 955-965 (2008).
I would like to know if the 3T3 cells seeded are not confluent in the 6-well plate after 24 hours incubation, can the plate be used for co-culture with PBMC?
You must be signed in to post a comment. Please sign in or create an account.
You are absolutely right. It would be much simpler to use a soluble ligand instead of the CD40L-expressing cell line. Unfortunately, none of the ligands we tested worked for our purpose. All were able to induce activation of B cells but none of them induced the robust proliferation that we observe with the CD40L-expressing NIH3T3 cells. The only ligand that was able to induce proliferation was a trimeric ligand produced by Immunex. Howerver, to our regret Immunex stopped its development and it is not available anymore.
You must be signed in to post a comment. Please sign in or create an account.
Apart from research developments, what do you think about the use of CD40L-stimulated B cells in clinical settings (such as cellular adiuvants), and how, in these cases, can we avoid the use of reagents and cells not adequate?
You must be signed in to post a comment. Please sign in or create an account.
Hi,
I am encountering problem with the feeder cell monolayer, after putting the B-Cells on the top of monolayer, cells from monolayer it starts coming up and ultimately leading to loss of B-cells too.
Have you any time encountered any such issue with monolayer (Cd40)?
1
ReplyPosted by: AnonymousOctober 21, 2009, 5:48 AM